HEMODYNAMIC-EFFECTS OF PROLONGED ENOXIMONE INFUSION (7 DAYS) IN PATIENTS WITH SEVERE CHRONIC HEART-FAILURE

被引:1
作者
GIBELIN, P [1 ]
DADOUNDYBAL, M [1 ]
CANDITO, M [1 ]
ROBILLON, JF [1 ]
MORAND, P [1 ]
机构
[1] HOP LOUIS PASTEUR,SERV CARDIOL,BP 69,F-06002 NICE 1,FRANCE
关键词
HEART FAILURE; ENOXIMONE; HEMODYNAMICS;
D O I
10.1007/BF00880156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study investigated the hemodynamic effects and tolerance of infusion of 10 mug/kg/min enoximone over 7 days in 12 patients (mean age 64.3 years) with severe chronic heart failure (10 NYHA Class III and 2 Class IV) with idiopathic dilated cardiomyopathy. Hemodynamic parameters were measured 10 minutes, 3 hours, 6 hours, 18 hours, 24 hours, and 7 days after the start of infusion. Catecholamines were assayed before the start of the infusion and on day 7. The heart rate increased on an average from 90.8 +/- 13.7 before infusion to 108.5 +/- 8.2 beats/min (p < 0.05) on day 7 (+ 20%). The mean arterial pressure decreased by approximately 10% (p < 0.05) between the start and end of the infusion. The pulmonary artery diastolic pressure dropped by a maximum of 30% at the 24th hour (23.1 +/- 5.1 to 16 +/- 5.4 mm Hg; p < 0.01). This decrease remained significant on day 7; the index cardiac was increased a maximum of 40% between the 18th and the 24th hour; p < 0.01). This increase was still significant on day 7 (2.35 +/- 0.44; p < 0.05; + 22%). Finally, the decrease in systemic arterial resistance, which reached a maximum of 30% of the 24th hour, persisted on day 7 (- 22%); 2076 +/- 451 to 1612 +/- 283 dynes/sec/cm5; p < 0.05). The norepinephrine level did not change significantly (4.5 +/1. 2 nmol/l before infusion vs. 4.2 +/- 1.1 nmol/l on day 7). Infusion had to be stopped in one patient after 30 minutes because of prolonged severe hypotension. Frequent supraventricular extrasystoles were observed in another patient during the entire period of infusion. In conclusion, a beneficial hemodynamic effect persisted on day 7 of enoximone infusion in patients with chronic heart failure, and clinical and biologic tolerance were good despite moderate tachycardia.
引用
收藏
页码:333 / 336
页数:4
相关论文
共 18 条
[1]   INTERMITTENT, CONTINUOUS OUTPATIENT DOBUTAMINE INFUSION IN THE MANAGEMENT OF CONGESTIVE HEART-FAILURE [J].
APPLEFELD, MM ;
NEWMAN, KA ;
GROVE, WR ;
SUTTON, FJ ;
ROFFMAN, DS ;
REED, WP ;
LINBERG, SE .
AMERICAN JOURNAL OF CARDIOLOGY, 1983, 51 (03) :455-458
[2]  
BRISTOW MR, 1989, BR J CLIN PRACT S64, V42, P69
[3]  
CHATTERJEE K, 1989, BR J CLIN PRAC S64, V42, P19
[4]   NEW POSITIVE INOTROPIC AGENTS IN THE TREATMENT OF CONGESTIVE-HEART-FAILURE - MECHANISMS OF ACTION AND RECENT CLINICAL DEVELOPMENTS .1. [J].
COLUCCI, WS ;
WRIGHT, RF ;
BRAUNWALD, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (05) :290-299
[5]  
DELANGENHAGEN B, 1990, ARCH MAL COEUR VAISS, V83, P19
[6]  
DREYFUS G, 1989, LANCET, V1, P153
[7]   HEMODYNAMIC-EFFECTS OF PROLONGED INTRAVENOUS THERAPY WITH ENOXIMONE IN PATIENTS WITH SEVERE CONGESTIVE HEART-FAILURE [J].
FERRY, DR ;
KENNEDY, GT ;
OROURKE, RA ;
CRAWFORD, MH .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 11 (01) :115-122
[8]  
GALINIER M, 1990, ARCH MAL COEUR VAISS, V83, P27
[9]  
GIBELIN P, 1990, ARCH MAL COEUR VAISS, V83, P75
[10]  
GILBERT EM, 1987, AM J CARDIOL, V60, P57